Index - P/E - EPS (ttm) -1.32 Insider Own 1.04% Shs Outstand 184.53M Perf Week -5.85%
Market Cap 9.30B Forward P/E - EPS next Y -0.01 Insider Trans -5.35% Shs Float 182.61M Perf Month -20.64%
Income -240.23M PEG - EPS next Q -0.33 Inst Own 89.57% Short Float 4.86% Perf Quarter -17.37%
Sales 2.53B P/S 3.67 EPS this Y 0.33% Inst Trans -1.72% Short Ratio 3.19 Perf Half Y -20.18%
Book/sh 17.04 P/B 2.96 EPS next Y 98.88% ROA -3.79% Short Interest 8.88M Perf Year -35.93%
Cash/sh 3.53 P/C 14.26 EPS next 5Y - ROE -7.76% 52W Range 51.91 - 100.77 Perf YTD -31.90%
Dividend Est. - P/FCF - EPS past 5Y 4.59% ROI -4.47% 52W High -50.00% Beta 1.28
Dividend TTM - Quick Ratio 1.45 Sales past 5Y 43.88% Gross Margin 70.02% 52W Low -2.95% ATR (14) 2.99
Dividend Ex-Date - Current Ratio 1.64 EPS Y/Y TTM 54.59% Oper. Margin -13.24% RSI (14) 28.89 Volatility 4.64% 4.59%
Employees 6600 Debt/Eq 0.82 Sales Y/Y TTM 15.21% Profit Margin -9.48% Recom 1.33 Target Price 86.61
Option/Short Yes / Yes LT Debt/Eq 0.72 EPS Q/Q -45.59% Payout - Rel Volume 0.88 Prev Close 51.95
Sales Surprise 1.10% EPS Surprise -26.32% Sales Q/Q 5.82% Earnings May 08 AMC Avg Volume 2.78M Price 50.38
SMA20 -14.27% SMA50 -19.90% SMA200 -25.21% Trades
Volume 2,450,524 Change -3.02%
Date
Action
Analyst
Rating Change
Price Target Change
Jan-02-24 Upgrade The Benchmark Company
Hold → Buy
$91
Dec-14-23 Initiated Guggenheim
Buy
$90
Dec-13-23 Initiated Wolfe Research
Outperform
$95
Oct-10-23 Upgrade Piper Sandler
Neutral → Overweight
$90
Sep-28-23 Initiated Bernstein
Outperform
$83
Aug-02-23 Downgrade The Benchmark Company
Buy → Hold
May-10-23 Upgrade Craig Hallum
Hold → Buy
$55 → $85
May-05-23 Initiated UBS
Neutral
$73
Mar-09-23 Upgrade Citigroup
Neutral → Buy
$70 → $90
Feb-10-23 Downgrade Credit Suisse
Outperform → Neutral
$50 → $70
Jan-18-23 Downgrade Raymond James
Outperform → Mkt Perform
Oct-19-22 Downgrade Craig Hallum
Buy → Hold
$60 → $35
Aug-25-22 Initiated Credit Suisse
Outperform
$55
Jun-03-22 Initiated Piper Sandler
Neutral
$50
Nov-03-21 Downgrade Raymond James
Strong Buy → Outperform
$160 → $130
Jul-29-21 Reiterated Stifel
Buy
$165 → $145
Jul-29-21 Reiterated Oppenheimer
Outperform
$161 → $155
Jul-29-21 Reiterated Canaccord Genuity
Buy
$185 → $160
Jul-29-21 Reiterated BTIG Research
Buy
$155 → $145
Jun-15-21 Initiated Raymond James
Strong Buy
$160
Show Previous Ratings
May-17-24 06:27AM
May-10-24 12:27PM
09:22AM
May-09-24 04:02PM
(Investor's Business Daily) -8.96%
12:29PM
11:41AM
Loading…
11:41AM
11:02AM
09:59AM
(Thomson Reuters StreetEvents)
07:29AM
03:53AM
01:06AM
May-08-24 11:30PM
06:05PM
05:02PM
(Associated Press Finance)
04:05PM
08:00AM
Loading…
May-07-24 08:00AM
May-06-24 08:52AM
May-01-24 06:00AM
Apr-25-24 08:05PM
(Morningstar Research) -7.04%
Apr-24-24 06:15PM
07:16AM
Apr-22-24 12:44PM
11:10AM
Apr-17-24 06:15PM
Apr-15-24 06:52AM
06:00AM
Apr-12-24 07:00AM
06:49AM
06:40AM
Apr-11-24 06:00AM
06:15PM
Loading…
Apr-10-24 06:15PM
08:16AM
12:00AM
Apr-09-24 07:37AM
Apr-08-24 12:05PM
07:00AM
(The Wall Street Journal)
06:00AM
Apr-05-24 10:16AM
Apr-04-24 10:15AM
06:05AM
Apr-03-24 09:57AM
Apr-02-24 04:02PM
(Investor's Business Daily)
Mar-29-24 08:09AM
Mar-28-24 06:00AM
Mar-27-24 08:05AM
Mar-26-24 07:00AM
Mar-25-24 09:55AM
Mar-22-24 11:30AM
Mar-18-24 08:19AM
04:30AM
Mar-14-24 04:16PM
(Investor's Business Daily)
Mar-13-24 05:03PM
Mar-11-24 12:59AM
Mar-08-24 09:55AM
Mar-07-24 07:59AM
Mar-04-24 11:52PM
03:49PM
10:38AM
Mar-03-24 10:32AM
Feb-26-24 06:00AM
Feb-23-24 12:01PM
Feb-22-24 11:08AM
10:30AM
(Thomson Reuters StreetEvents)
10:22AM
01:30AM
12:06AM
Feb-21-24 06:20PM
05:41PM
(Associated Press Finance)
05:12PM
04:05PM
Feb-20-24 02:39AM
Feb-15-24 07:47AM
Feb-14-24 10:00AM
Feb-13-24 08:12PM
Feb-10-24 05:06PM
Feb-07-24 09:00AM
Feb-01-24 06:00AM
Jan-28-24 09:25AM
Jan-22-24 08:00AM
Jan-18-24 05:04AM
Jan-13-24 02:05PM
Jan-08-24 02:48PM
Jan-07-24 04:30PM
Jan-02-24 06:00AM
Dec-21-23 09:43AM
Dec-20-23 01:49PM
Dec-17-23 05:43AM
Dec-14-23 04:02AM
Dec-13-23 12:52PM
08:45AM
Dec-07-23 08:05AM
Dec-05-23 09:11AM
Dec-04-23 12:13PM
Dec-01-23 11:32AM
05:26AM
Nov-30-23 04:05PM
Nov-25-23 09:45AM
Nov-23-23 12:02PM
Nov-20-23 03:06PM
09:55AM
EXACT Sciences Corp. is a cancer screening and diagnostics company. The firm focuses on the early detection and prevention of some forms of cancer. It offers a non-invasive screening test called Cologuard for the early detection of colorectal cancer and pre-cancer and Oncotype DX. The company was founded on February 10, 1995, and is headquartered in Madison, WI.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Conroy Kevin T President and CEO May 01 '24 Sale 60.15 1,155 69,473 1,156,191 May 02 07:00 PM Cunningham Everett Chief Commercial Officer May 01 '24 Sale 60.15 136 8,180 47,042 May 02 07:00 PM Elliott Jeffrey Thomas Chief Financial Officer May 01 '24 Sale 60.15 136 8,180 11,795 May 02 07:00 PM Baranick Brian EVP, GM., Precision Oncology May 01 '24 Sale 60.15 110 6,616 13,279 May 02 07:00 PM ORVILLE JACOB A General Manager, Screening May 01 '24 Sale 60.15 102 6,135 14,440 May 02 07:00 PM Condella Sarah EVP, Human Resources May 01 '24 Sale 60.15 102 6,135 72,611 May 02 07:00 PM COWARD D SCOTT Director May 01 '24 Sale 60.15 67 4,030 44,644 May 02 07:00 PM Herriott James SVP, General Counsel & Sec May 01 '24 Sale 60.15 30 1,804 9,866 May 02 07:00 PM Baranick Brian EVP, GM., Precision Oncology Apr 02 '24 Sale 79.43 924 73,393 13,171 Apr 03 07:30 PM Condella Sarah EVP, Human Resources Apr 01 '24 Sale 70.00 2,000 140,000 71,787 Apr 03 07:30 PM Condella Sarah EVP, Human Resources Mar 28 '24 Sale 70.00 2,000 140,000 73,787 Apr 01 04:30 PM Conroy Kevin T President and CEO Mar 01 '24 Sale 59.32 8,271 490,636 1,299,496 Mar 04 08:38 PM LEVANGIE DANIEL J Director Mar 01 '24 Sale 57.50 5,000 287,500 22,975 Mar 04 08:42 PM Cunningham Everett Chief Commercial Officer Mar 01 '24 Sale 59.32 2,412 143,080 46,179 Mar 04 08:38 PM Elliott Jeffrey Thomas Chief Financial Officer Mar 01 '24 Sale 59.32 2,412 143,080 10,933 Mar 04 08:40 PM Baranick Brian Gen. Mgr., Precision Oncology Mar 01 '24 Sale 59.32 2,323 137,800 14,095 Mar 04 08:36 PM ORVILLE JACOB A General Manager, Screening Mar 01 '24 Sale 59.32 2,154 127,775 14,324 Mar 04 08:42 PM Doyle James Edward Director Mar 01 '24 Sale 57.50 2,000 115,000 50,110 Mar 04 08:39 PM Condella Sarah EVP, Human Resources Mar 01 '24 Sale 59.32 1,724 102,268 75,787 Mar 04 08:37 PM Herriott James General Counsel Mar 01 '24 Sale 59.32 862 51,134 9,125 Mar 04 08:41 PM Elliott Jeffrey Thomas Chief Financial Officer Feb 29 '24 Option Exercise 0.00 5,291 0 13,345 Mar 04 08:40 PM Cunningham Everett Chief Commercial Officer Feb 29 '24 Option Exercise 0.00 5,291 0 48,591 Mar 04 08:38 PM Herriott James General Counsel Feb 29 '24 Option Exercise 0.00 1,890 0 9,987 Mar 04 08:41 PM Baranick Brian Gen. Mgr., Precision Oncology Feb 29 '24 Option Exercise 0.00 4,724 0 16,418 Mar 04 08:36 PM Condella Sarah EVP, Human Resources Feb 29 '24 Option Exercise 0.00 3,779 0 77,511 Mar 04 08:37 PM Conroy Kevin T President and CEO Feb 29 '24 Option Exercise 0.00 18,143 0 1,307,767 Mar 04 08:38 PM ORVILLE JACOB A General Manager, Screening Feb 29 '24 Option Exercise 0.00 4,724 0 16,478 Mar 04 08:42 PM Conroy Kevin T President and CEO Feb 27 '24 Sale 56.89 6,263 356,302 1,289,624 Feb 28 07:35 PM Cunningham Everett Chief Commercial Officer Feb 27 '24 Sale 56.89 3,648 207,535 43,300 Feb 28 07:37 PM Elliott Jeffrey Thomas Chief Financial Officer Feb 27 '24 Sale 56.89 2,710 154,172 8,054 Feb 28 07:36 PM Baranick Brian Gen. Mgr., Precision Oncology Feb 27 '24 Sale 56.89 2,027 115,316 11,694 Feb 28 07:34 PM Condella Sarah EVP, Human Resources Feb 27 '24 Sale 56.89 1,880 106,953 73,732 Feb 28 07:35 PM ORVILLE JACOB A General Manager, Screening Feb 27 '24 Sale 56.89 1,879 106,896 11,754 Feb 28 07:38 PM Herriott James General Counsel Feb 27 '24 Sale 56.89 784 44,602 8,097 Feb 28 07:38 PM ORVILLE JACOB A General Manager, Screening Feb 26 '24 Option Exercise 0.00 3,954 0 13,633 Feb 28 07:38 PM Cunningham Everett Chief Commercial Officer Feb 26 '24 Option Exercise 0.00 7,678 0 46,948 Feb 28 07:37 PM Herriott James General Counsel Feb 26 '24 Option Exercise 0.00 1,648 0 8,881 Feb 28 07:38 PM Elliott Jeffrey Thomas Chief Financial Officer Feb 26 '24 Option Exercise 0.00 5,701 0 10,764 Feb 28 07:36 PM Condella Sarah EVP, Human Resources Feb 26 '24 Option Exercise 0.00 3,954 0 75,612 Feb 28 07:35 PM Conroy Kevin T President and CEO Feb 26 '24 Option Exercise 0.00 13,181 0 1,295,887 Feb 28 07:35 PM Baranick Brian Gen. Mgr., Precision Oncology Feb 26 '24 Option Exercise 0.00 3,954 0 13,721 Feb 28 07:34 PM Conroy Kevin T President and CEO Feb 23 '24 Option Exercise 13.96 102,837 1,435,605 1,344,266 Feb 26 05:00 PM Condella Sarah EVP, Human Resources Feb 23 '24 Sale 59.72 1,021 60,974 71,658 Feb 26 05:00 PM Conroy Kevin T President and CEO Feb 22 '24 Sale 59.78 11,565 691,356 1,241,429 Feb 23 07:59 PM Elliott Jeffrey Thomas Chief Financial Officer Feb 22 '24 Sale 59.78 1,351 80,763 5,063 Feb 23 08:01 PM Cunningham Everett Chief Commercial Officer Feb 22 '24 Sale 59.78 1,350 80,703 39,270 Feb 23 08:00 PM Baranick Brian Gen. Mgr., Precision Oncology Feb 22 '24 Sale 59.78 1,093 65,340 9,767 Feb 23 07:57 PM Condella Sarah EVP, Human Resources Feb 22 '24 Sale 59.78 1,013 60,557 72,679 Feb 23 07:57 PM ORVILLE JACOB A General Manager, Screening Feb 22 '24 Sale 59.78 1,013 60,557 9,679 Feb 23 08:03 PM COWARD D SCOTT Director Feb 22 '24 Sale 59.78 663 39,634 44,493 Feb 23 07:59 PM Herriott James General Counsel Feb 22 '24 Sale 59.78 291 17,396 7,233 Feb 23 08:02 PM Conroy Kevin T President and CEO Feb 21 '24 Sale 61.50 4,975 305,962 1,229,756 Feb 22 07:37 PM Elliott Jeffrey Thomas Chief Financial Officer Feb 21 '24 Sale 61.50 1,493 91,820 3,703 Feb 22 07:38 PM Condella Sarah EVP, Human Resources Feb 21 '24 Sale 61.50 1,079 66,358 71,658 Feb 22 07:36 PM ORVILLE JACOB A General Manager, Screening Feb 21 '24 Sale 61.50 1,078 66,297 8,658 Feb 22 07:40 PM Baranick Brian Gen. Mgr., Precision Oncology Feb 21 '24 Sale 61.50 895 55,042 8,826 Feb 22 07:36 PM COWARD D SCOTT Director Feb 21 '24 Sale 61.50 706 43,419 43,122 Feb 22 07:38 PM Herriott James General Counsel Feb 21 '24 Sale 61.50 415 25,522 6,943 Feb 22 07:39 PM Elliott Jeffrey Thomas Chief Financial Officer Feb 20 '24 Option Exercise 0.00 3,112 0 5,196 Feb 22 07:38 PM Conroy Kevin T President and CEO Feb 20 '24 Option Exercise 0.00 10,374 0 1,234,731 Feb 22 07:37 PM COWARD D SCOTT Director Feb 20 '24 Option Exercise 0.00 2,248 0 43,828 Feb 22 07:38 PM Baranick Brian Gen. Mgr., Precision Oncology Feb 20 '24 Option Exercise 0.00 1,729 0 9,721 Feb 22 07:36 PM Condella Sarah EVP, Human Resources Feb 20 '24 Option Exercise 0.00 2,248 0 72,737 Feb 22 07:36 PM Herriott James General Counsel Feb 20 '24 Option Exercise 0.00 864 0 7,358 Feb 22 07:39 PM ORVILLE JACOB A General Manager, Screening Feb 20 '24 Option Exercise 0.00 2,248 0 9,736 Feb 22 07:40 PM Conroy Kevin T President and CEO Feb 15 '24 Sale 61.43 14,791 908,611 1,224,357 Feb 16 06:22 PM Elliott Jeffrey Thomas Chief Financial Officer Feb 15 '24 Sale 61.43 1,888 115,980 2,084 Feb 16 06:24 PM COWARD D SCOTT Director Feb 15 '24 Sale 61.43 1,376 84,528 41,580 Feb 16 06:23 PM ORVILLE JACOB A General Manager, Screening Feb 15 '24 Sale 61.43 966 59,341 7,488 Feb 16 06:26 PM Condella Sarah EVP, Human Resources Feb 15 '24 Sale 61.43 965 59,280 70,489 Feb 16 06:21 PM Herriott James General Counsel Feb 15 '24 Sale 61.43 421 25,862 6,494 Feb 16 06:25 PM ORVILLE JACOB A General Manager, Screening Feb 14 '24 Option Exercise 0.00 2,031 0 8,454 Feb 16 06:26 PM Elliott Jeffrey Thomas Chief Financial Officer Feb 14 '24 Option Exercise 0.00 3,972 0 3,972 Feb 16 06:24 PM COWARD D SCOTT Director Feb 14 '24 Option Exercise 0.00 3,972 0 42,956 Feb 16 06:23 PM Herriott James General Counsel Feb 14 '24 Option Exercise 0.00 883 0 6,915 Feb 16 06:25 PM Condella Sarah EVP, Human Resources Feb 14 '24 Option Exercise 0.00 2,031 0 71,454 Feb 16 06:21 PM Conroy Kevin T President and CEO Feb 14 '24 Option Exercise 0.00 31,133 0 1,239,148 Feb 16 06:22 PM Condella Sarah EVP, Human Resources Jan 02 '24 Sale 73.50 2,000 147,000 69,423 Jan 04 05:19 PM Baranick Brian Gen. Mgr., Precision Oncology Jan 02 '24 Sale 73.50 879 64,606 7,992 Jan 04 05:17 PM Condella Sarah EVP, Human Resources Dec 14 '23 Sale 70.00 2,000 140,000 71,423 Dec 18 07:49 PM Cunningham Everett Chief Commercial Officer Oct 12 '23 Sale 66.49 13,007 864,835 37,909 Oct 13 07:59 PM Cunningham Everett Chief Commercial Officer Oct 11 '23 Option Exercise 0.00 27,504 0 50,916 Oct 13 07:59 PM Condella Sarah EVP, Human Resources Sep 01 '23 Sale 84.36 4,500 379,620 75,814 Sep 06 04:04 PM Elliott Jeffrey Thomas Chief Financial Officer Aug 21 '23 Sale 82.92 30,210 2,505,013 0 Aug 23 04:08 PM Baranick Brian Gen. Mgr., Precision Oncology Aug 07 '23 Sale 85.04 1,350 114,804 8,871 Aug 08 04:09 PM Baranick Brian Gen. Mgr., Precision Oncology Aug 04 '23 Option Exercise 0.00 2,712 0 10,221 Aug 08 04:09 PM Doyle James Edward Director Jul 27 '23 Sale 97.42 2,000 194,840 52,110 Jul 28 04:06 PM Herriott James General Counsel Jul 19 '23 Sale 100.00 1,300 130,000 5,964 Jul 21 04:04 PM Zanotti Katherine S Director Jun 09 '23 Sale 90.51 3,027 273,974 64,629 Jun 12 04:17 PM Doyle James Edward Director Jun 09 '23 Sale 90.51 1,402 126,895 54,110 Jun 12 04:29 PM Herriott James General Counsel Jun 08 '23 Sale 90.00 1,300 117,000 7,264 Jun 12 04:14 PM Doyle James Edward Director May 26 '23 Sale 80.62 2,000 161,240 51,913 May 31 04:13 PM
Index - P/E - EPS (ttm) -1.81 Insider Own 9.96% Shs Outstand 107.08M Perf Week 33.52%
Market Cap 2.37B Forward P/E - EPS next Y -1.76 Insider Trans -0.10% Shs Float 97.23M Perf Month 82.49%
Income -192.74M PEG - EPS next Q -0.41 Inst Own 83.77% Short Float 5.80% Perf Quarter 36.25%
Sales 525.66M P/S 4.50 EPS this Y 15.93% Inst Trans 2.95% Short Ratio 4.15 Perf Half Y 73.42%
Book/sh 3.34 P/B 6.58 EPS next Y -7.26% ROA -16.79% Short Interest 5.64M Perf Year -71.97%
Cash/sh 8.12 P/C 2.71 EPS next 5Y - ROE -48.70% 52W Range 10.87 - 83.47 Perf YTD 47.29%
Dividend Est. - P/FCF - EPS past 5Y -22.97% ROI -20.19% 52W High -73.66% Beta 0.80
Dividend TTM - Quick Ratio 5.99 Sales past 5Y 17.16% Gross Margin 74.97% 52W Low 102.30% ATR (14) 1.08
Dividend Ex-Date - Current Ratio 6.26 EPS Y/Y TTM -34.69% Oper. Margin -39.07% RSI (14) 84.57 Volatility 8.54% 6.43%
Employees 1453 Debt/Eq 1.66 Sales Y/Y TTM 0.61% Profit Margin -36.67% Recom 2.14 Target Price 25.50
Option/Short Yes / Yes LT Debt/Eq 1.66 EPS Q/Q 28.06% Payout - Rel Volume 0.85 Prev Close 22.17
Sales Surprise 5.37% EPS Surprise 14.29% Sales Q/Q 13.36% Earnings May 02 BMO Avg Volume 1.36M Price 21.99
SMA20 46.04% SMA50 51.17% SMA200 35.93% Trades
Volume 1,150,050 Change -0.81%
Date
Action
Analyst
Rating Change
Price Target Change
Nov-20-23 Resumed JP Morgan
Neutral
$15
Aug-28-23 Downgrade H.C. Wainwright
Buy → Neutral
$85 → $25
Aug-08-23 Upgrade Piper Sandler
Neutral → Overweight
$45
Aug-04-23 Initiated SVB Securities
Outperform
$51
Jul-31-23 Upgrade Evercore ISI
Underperform → In-line
$33
Jun-07-23 Upgrade Wedbush
Underperform → Neutral
$53 → $46
May-16-23 Upgrade Wells Fargo
Equal Weight → Overweight
$70 → $104
Mar-17-23 Downgrade JP Morgan
Neutral → Underweight
$99 → $50
Jan-06-23 Downgrade Wells Fargo
Overweight → Equal Weight
$89 → $107
Jan-05-23 Reiterated H.C. Wainwright
Buy
$100 → $140
Nov-29-22 Upgrade Wells Fargo
Equal Weight → Overweight
$74 → $89
Oct-24-22 Downgrade Piper Sandler
Overweight → Neutral
$90 → $70
Jul-05-22 Downgrade Evercore ISI
In-line → Underperform
May-16-22 Initiated H.C. Wainwright
Buy
$115
Feb-08-22 Initiated Loop Capital
Buy
$200
Feb-02-22 Upgrade Oppenheimer
Perform → Outperform
$98
Jan-20-22 Upgrade Truist
Hold → Buy
$125
Jan-03-22 Upgrade Evercore ISI
Underperform → In-line
$82
Jul-01-21 Downgrade Mizuho
Buy → Neutral
Apr-14-21 Downgrade Wedbush
Neutral → Underperform
$159 → $154
Show Previous Ratings
May-14-24 07:08AM
May-10-24 05:14PM
May-03-24 12:08PM
01:00AM
May-02-24 01:19PM
11:56AM
Loading…
11:56AM
08:45AM
08:25AM
07:28AM
(Associated Press Finance)
07:01AM
07:00AM
Apr-25-24 10:01AM
Apr-24-24 10:45AM
Apr-05-24 07:00AM
Apr-04-24 11:33AM
12:00PM
Loading…
Apr-01-24 12:00PM
07:00AM
Mar-30-24 06:34AM
Mar-28-24 11:50AM
05:01AM
Mar-27-24 04:08PM
(Investor's Business Daily) +12.01%
09:29AM
09:16AM
(Investor's Business Daily)
07:14AM
07:12AM
07:05AM
07:00AM
Mar-13-24 09:55AM
Mar-11-24 07:00AM
Feb-23-24 11:43AM
12:15PM
Loading…
Feb-22-24 12:15PM
08:25AM
07:36AM
07:23AM
(Associated Press Finance)
07:00AM
Jan-19-24 07:46AM
Jan-18-24 02:19PM
07:00AM
Jan-11-24 09:55AM
Jan-09-24 07:00AM
Jan-08-24 07:00AM
Jan-04-24 04:05PM
Dec-27-23 07:00AM
Dec-08-23 04:09AM
Dec-04-23 04:46PM
Nov-28-23 10:51AM
07:30AM
Nov-21-23 07:00AM
Nov-14-23 09:09AM
Nov-10-23 08:00AM
Nov-03-23 06:45AM
Oct-30-23 02:04AM
Oct-28-23 08:39AM
Oct-26-23 04:35PM
11:00AM
08:52AM
08:30AM
07:24AM
(Associated Press Finance)
07:00AM
Oct-15-23 06:05PM
Oct-12-23 08:00AM
Oct-02-23 07:00AM
Sep-29-23 05:00PM
Sep-18-23 11:47AM
Sep-08-23 04:01PM
Sep-06-23 02:27PM
Sep-04-23 09:30AM
Aug-31-23 06:52PM
09:55AM
Aug-29-23 06:31PM
Aug-28-23 05:15PM
04:08PM
(Investor's Business Daily)
02:19PM
(Investor's Business Daily)
12:21PM
12:16PM
12:10PM
11:47AM
09:34AM
07:27AM
07:10AM
07:00AM
Aug-25-23 08:20AM
07:00AM
Aug-15-23 09:30AM
Aug-13-23 05:49PM
Aug-09-23 10:45AM
05:10AM
Aug-08-23 04:11PM
10:02AM
Aug-04-23 09:38AM
Aug-01-23 03:54PM
Jul-27-23 06:56PM
11:30AM
08:15AM
07:07AM
07:00AM
Jul-25-23 10:01AM
Jul-21-23 08:00AM
Jul-06-23 01:17PM
Jul-03-23 08:00AM
NovoCure Ltd. is an oncology company which engages in the development, manufacture, and commercialization of Optune for the treatment of a variety of solid tumors. Its platform is called the Tumor Treating Field which uses electric fields tuned to specific frequencies to disrupt solid tumor cancer cell division. The company was founded by Yoram Palti in 2000 and is headquartered in St. Helier, Jersey.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
GROENHUYSEN WILHELMUS CM Chief Operating Officer Mar 04 '24 Sale 16.01 1,217 19,484 251,235 Mar 05 04:09 PM Leonard Frank X EVP, Pres., Novocure Oncology Mar 04 '24 Sale 16.01 840 13,448 160,098 Mar 05 04:08 PM GROENHUYSEN WILHELMUS CM Chief Operating Officer Mar 01 '24 Sale 16.03 2,107 33,769 252,452 Mar 05 04:09 PM Leonard Frank X EVP, Pres., Novocure Oncology Mar 01 '24 Sale 16.03 1,679 26,909 160,938 Mar 05 04:08 PM GROENHUYSEN WILHELMUS CM Chief Operating Officer Feb 28 '24 Sale 16.14 2,303 37,177 254,559 Feb 29 04:28 PM Leonard Frank X EVP, Pres., Novocure Oncology Feb 28 '24 Sale 16.14 2,078 33,545 162,617 Feb 29 04:38 PM Shah Pritesh Chief Growth Officer Nov 07 '23 Sale 12.65 382 4,832 124,511 Nov 08 04:22 PM Cordova Ashley Chief Financial Officer Nov 02 '23 Option Exercise 11.46 175 2,006 117,618 Nov 02 04:20 PM Cordova Ashley Chief Financial Officer Oct 31 '23 Option Exercise 9.58 17,793 170,447 117,443 Nov 02 04:20 PM Cordova Ashley Chief Financial Officer Sep 01 '23 Sale 21.82 883 19,265 99,650 Sep 05 04:24 PM GROENHUYSEN WILHELMUS CM Chief Operating Officer Sep 01 '23 Sale 21.82 294 6,414 209,825 Sep 05 04:24 PM Shah Pritesh Chief Growth Officer Sep 01 '23 Sale 21.82 273 5,956 124,893 Sep 05 04:23 PM Cordova Ashley Chief Financial Officer Aug 02 '23 Sale 30.25 1,144 34,607 100,533 Aug 04 04:02 PM
Index S&P 500 P/E 56.64 EPS (ttm) 3.31 Insider Own 0.64% Shs Outstand 69.91M Perf Week 12.88%
Market Cap 13.12B Forward P/E 50.03 EPS next Y 3.74 Insider Trans -2.54% Shs Float 69.59M Perf Month 13.68%
Income 234.00M PEG 3.80 EPS next Q 0.56 Inst Own 100.78% Short Float 4.23% Perf Quarter -1.96%
Sales 1.78B P/S 7.37 EPS this Y 4.81% Inst Trans -0.62% Short Ratio 3.02 Perf Half Y 7.94%
Book/sh 11.29 P/B 16.58 EPS next Y 21.48% ROA 9.53% Short Interest 2.94M Perf Year -40.20%
Cash/sh 10.73 P/C 17.46 EPS next 5Y 14.90% ROE 36.18% 52W Range 125.82 - 320.27 Perf YTD -13.69%
Dividend Est. - P/FCF 90.27 EPS past 5Y 122.47% ROI 10.87% 52W High -41.53% Beta 1.15
Dividend TTM - Quick Ratio 2.71 Sales past 5Y 24.75% Gross Margin 69.15% 52W Low 48.84% ATR (14) 7.83
Dividend Ex-Date - Current Ratio 3.70 EPS Y/Y TTM 46422.22% Oper. Margin 13.99% RSI (14) 61.45 Volatility 5.22% 4.30%
Employees 3000 Debt/Eq 1.77 Sales Y/Y TTM 30.17% Profit Margin 13.14% Recom 1.42 Target Price 232.49
Option/Short Yes / Yes LT Debt/Eq 1.72 EPS Q/Q 116.08% Payout 0.00% Rel Volume 0.74 Prev Close 185.38
Sales Surprise 4.16% EPS Surprise 81.95% Sales Q/Q 23.35% Earnings May 09 AMC Avg Volume 973.69K Price 187.27
SMA20 9.04% SMA50 9.43% SMA200 3.51% Trades
Volume 723,326 Change 1.02%
Date
Action
Analyst
Rating Change
Price Target Change
May-07-24 Upgrade Wolfe Research
Peer Perform → Outperform
$200
Dec-21-23 Upgrade Robert W. Baird
Neutral → Outperform
$180 → $238
Dec-04-23 Upgrade Morgan Stanley
Equal-Weight → Overweight
$185 → $234
Oct-02-23 Upgrade Jefferies
Hold → Buy
$260 → $240
Aug-21-23 Upgrade Citigroup
Neutral → Buy
$273 → $265
Aug-21-23 Downgrade Robert W. Baird
Outperform → Neutral
$320 → $219
May-30-23 Resumed Morgan Stanley
Equal-Weight
$343
Jan-26-23 Initiated Wolfe Research
Peer Perform
Nov-04-22 Upgrade Piper Sandler
Neutral → Overweight
$235 → $340
Oct-18-22 Initiated Barclays
Equal Weight
$238
Oct-12-22 Initiated Jefferies
Hold
$260
Jul-11-22 Downgrade Citigroup
Buy → Neutral
$310 → $250
Mar-02-22 Resumed BofA Securities
Buy
$300
Feb-03-22 Upgrade BTIG Research
Neutral → Buy
$320
Feb-02-22 Upgrade UBS
Neutral → Buy
$325
Jan-31-22 Upgrade Oppenheimer
Perform → Outperform
$300 → $275
Jul-21-21 Resumed Cowen
Outperform
$285 → $310
May-25-21 Initiated Barclays
Overweight
$300
Apr-01-21 Upgrade SVB Leerink
Mkt Perform → Outperform
$275 → $320
Mar-19-21 Upgrade Canaccord Genuity
Hold → Buy
$280
Show Previous Ratings
May-16-24 07:42AM
May-14-24 04:47PM
04:44PM
03:58PM
11:19AM
10:48AM
Loading…
May-13-24 10:48AM
May-10-24 04:55PM
03:25PM
12:24PM
09:43AM
09:24AM
08:10AM
08:00AM
07:49AM
May-09-24 08:57PM
05:30PM
Loading…
05:30PM
04:30PM
04:11PM
(Associated Press Finance)
04:01PM
10:16AM
May-07-24 06:00AM
May-06-24 09:16AM
May-02-24 06:15PM
09:50AM
Apr-28-24 05:50PM
Apr-26-24 06:15PM
Apr-24-24 08:42AM
Apr-15-24 09:45AM
Apr-12-24 12:10PM
Apr-10-24 06:15PM
06:00AM
Loading…
Apr-03-24 06:00AM
Apr-02-24 09:45AM
Mar-28-24 09:55AM
Mar-26-24 05:10AM
Mar-21-24 09:17AM
06:40AM
Mar-20-24 08:11AM
06:00AM
Mar-19-24 06:39AM
06:14AM
Mar-18-24 08:23AM
Mar-14-24 09:45AM
Mar-08-24 06:00AM
Mar-05-24 06:00AM
Mar-04-24 05:30AM
Feb-29-24 07:12AM
Feb-28-24 08:59AM
Feb-27-24 09:35AM
Feb-26-24 06:04PM
(Morningstar Research) -8.35%
Feb-23-24 12:40PM
12:30PM
(Associated Press Finance)
12:10PM
08:40AM
(Thomson Reuters StreetEvents)
Feb-22-24 06:00PM
05:20PM
04:32PM
04:18PM
(Associated Press Finance)
04:07PM
04:07PM
Feb-19-24 09:15AM
Feb-18-24 01:26PM
Feb-16-24 08:27AM
Feb-13-24 04:01PM
Feb-12-24 10:01AM
Feb-08-24 09:52AM
04:45AM
Feb-07-24 06:00AM
Feb-05-24 12:45PM
Feb-01-24 10:26AM
Jan-31-24 08:13PM
Jan-22-24 09:45AM
Jan-18-24 04:01PM
Jan-12-24 09:37AM
Jan-11-24 06:00AM
Jan-08-24 09:51AM
Jan-05-24 09:45AM
Dec-29-23 12:45PM
Dec-28-23 01:13PM
09:01AM
Dec-26-23 02:30PM
Dec-21-23 01:31AM
Dec-20-23 05:14AM
Dec-14-23 07:56PM
Dec-13-23 12:45PM
Dec-11-23 04:32PM
Dec-08-23 05:33AM
05:26AM
Dec-07-23 04:42AM
Dec-04-23 09:53AM
Nov-30-23 04:45PM
12:43PM
Nov-28-23 06:00AM
Nov-27-23 12:45PM
Nov-26-23 03:11PM
Nov-23-23 11:46AM
11:30AM
Nov-19-23 06:10AM
Nov-17-23 10:54AM
(The Wall Street Journal)
08:45AM
Nov-13-23 09:31AM
(Yahoo Finance Video) +5.55%
Insulet Corp. is a medical device company, which engages in the development, manufacture, and marketing of an insulin infusion system for people with insulin-dependent diabetes. It specializes in diabetes supplies, including the OmniPod System, as well as other diabetes related products and supplies such as blood glucose testing supplies, traditional insulin pumps, pump supplies, and pharmaceuticals. The company was founded by John L. Brooks III and John T. Garibotto in July 2000 and is headquartered in Acton, MA.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Petrovic Shacey Director Feb 28 '24 Option Exercise 92.11 11,609 1,069,305 14,176 Feb 29 04:37 PM Petrovic Shacey Director Feb 28 '24 Sale 162.92 11,609 1,891,338 2,567 Feb 29 04:37 PM BORIO LUCIANA Director Dec 15 '23 Sale 207.08 72 14,910 2,278 Dec 18 04:01 PM Petrovic Shacey Director Nov 13 '23 Option Exercise 81.69 20,000 1,633,733 22,567 Nov 14 04:04 PM Petrovic Shacey Director Nov 13 '23 Sale 164.33 20,000 3,286,600 2,567 Nov 14 04:04 PM Petrovic Shacey Director Nov 13 '23 Sale 165.02 15,000 2,475,300 0 Nov 14 04:04 PM Singh Prem SVP, Global Operations Sep 19 '23 Buy 168.92 1 169 4,032 Sep 21 04:48 PM Hollingshead James President and CEO Aug 28 '23 Buy 181.41 5,550 1,006,826 34,177 Aug 29 04:07 PM McMillan Wayde D. EVP, CFO Jul 03 '23 Sale 282.94 1,388 392,721 21,477 Jul 06 04:11 PM Manea Dan SVP, Chief HR Officer Jun 20 '23 Sale 290.00 175 50,750 4,522 Jun 21 04:09 PM BORIO LUCIANA Director Jun 05 '23 Sale 283.38 500 141,690 2,350 Jun 06 04:11 PM Petrovic Shacey Director Jun 01 '23 Sale 271.56 15,000 4,073,400 43,205 Jun 02 04:05 PM MINOGUE MICHAEL R Director May 23 '23 Buy 304.75 3,300 1,005,675 12,221 May 24 04:11 PM
×
Upgrade your FINVIZ experience
Join thousands of traders who make more informed decisions with our premium features.
Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite
